ArticleImmunity, inflammation and disease2022
The role of complement in the clinical course of hepatocellular carcinoma.
Article in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Identification of STEAP4, EPC1, and CLEC1B as non-invasive candidate biomarkers for hepatocellular carcinoma using integrated bioinformatics analysis.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC.Biomarker research · 2026Article
- Identification of prognostic biomarkers related to epithelial-mesenchymal transition and anoikis in hepatocellular carcinoma using transcriptomics and single-cell sequencing.Frontiers in cell and developmental biology · 2025Article
- An immune cell activation signature reflected hepatocellular carcinoma heterogeneity and predicted clinical outcomes.Frontiers in immunology · 2025Article
- A novel nomogram based on complement C3 to predict the overall survival of early-stage hepatocellular carcinoma patients with microvascular invasion-positive undergoing curative resection.Frontiers in oncology · 2025Article
- Investigating the diagnostic and prognostic significance of genes related to fatty acid metabolism in hepatocellular carcinoma.BMC gastroenterology · 2024Article
- Role of Complement in Liver Diseases.Seminars in liver disease · 2024Review
- C6 and KLRG2 are pyroptosis subtype-related prognostic biomarkers and correlated with tumor-infiltrating lymphocytes in lung adenocarcinoma.Scientific reports · 2024Article
- Article
- Identification of prognostic biomarkers for hepatocellular carcinoma with vascular invasion.American journal of translational research · 2024Article
- Modulation of the hepatic RANK-RANKL-OPG axis by combined C5 and CD14 inhibition in a long-term polytrauma model.Frontiers in immunology · 2024Article
- Article
- Current tests for diagnosis of hepatitis B virus infection and immune responses of HBV-related HCC.Frontiers in oncology · 2023Review
- The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system.Frontiers in pharmacology · 2023Article
- A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.BMC cancer · 2022Article
- The role of complement in the clinical course of hepatocellular carcinoma.Immunity, inflammation and disease · 2022Article
- An update on the role of complement in hepatocellular carcinoma.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe complement system, an innate immune system, may either play an antitumor role, or promote tumorigenesis and cancer progression in different kinds of cancer. The function of complement in hepatocellular carcinoma (HCC) is unclear.
methodsThe gene expressions of the complement system were based on data obtained from TCGA and GEO. We explored gene expressions, mutation, enrichment analysis, clinicopathology, patients' outcome, and immune infiltration via Gepia2, cBioPortal, Metascape, UALCAN, Kaplan-Meier Plotter, and TIMER 2.
resultsFive complement genes, including C1R, C6, C7, CFP, and CFHR3, were not only found to be significantly downregulated in HCC samples compared with normal liver samples, but also found to be significantly associated with overall survival, disease-free survival, and progress-free survival in HCC patients. In addition, lower mRNA expression of C1R, C6, C7, and CFHR3 were found correlated with advanced cancer stages and higher tumor grades in HCC patients. Also, the expression levels of CFP were correlated with many sets of immune markers of tumor immune cells, such as those of CD8+ T cells, CD4+ T cells, B cells, M2 macrophages, neutrophils, DCs, Th1 cells, Th2 cells, and T cell exhaustion in HCC. Based on that, we developed a prognostic model for HCC patients-Riskscore = (-0.0053)*C6+(-0.0498)*C7+(-0.1045)*CFHR3.
conclusionC1R, C6, C7, CFP, and CFHR3 could be prognostic biomarkers for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.